Department of Infectious Diseases, King's College London School of Medicine, London, United Kingdom.
PLoS Pathog. 2010 Jun 3;6(6):e1000925. doi: 10.1371/journal.ppat.1000925.
The HIV-1 viral infectivity factor (Vif) protein recruits an E3 ubiquitin ligase complex, comprising the cellular proteins elongin B and C (EloBC), cullin 5 (Cul5) and RING-box 2 (Rbx2), to the anti-viral proteins APOBEC3G (A3G) and APOBEC3F (A3F) and induces their polyubiquitination and proteasomal degradation. In this study, we used purified proteins and direct in vitro binding assays, isothermal titration calorimetry and NMR spectroscopy to describe the molecular mechanism for assembly of the Vif-EloBC ternary complex. We demonstrate that Vif binds to EloBC in two locations, and that both interactions induce structural changes in the SOCS box of Vif as well as EloBC. In particular, in addition to the previously established binding of Vif's BC box to EloC, we report a novel interaction between the conserved Pro-Pro-Leu-Pro motif of Vif and the C-terminal domain of EloB. Using cell-based assays, we further show that this interaction is necessary for the formation of a functional ligase complex, thus establishing a role of this motif. We conclude that HIV-1 Vif engages EloBC via an induced-folding mechanism that does not require additional co-factors, and speculate that these features distinguish Vif from other EloBC specificity factors such as cellular SOCS proteins, and may enhance the prospects of obtaining therapeutic inhibitors of Vif function.
HIV-1 病毒感染力因子 (Vif) 蛋白招募一种 E3 泛素连接酶复合物,包括细胞蛋白 elongin B 和 C (EloBC)、cullin 5 (Cul5) 和 RING-box 2 (Rbx2),靶向抗病毒蛋白 APOBEC3G (A3G) 和 APOBEC3F (A3F),并诱导它们多泛素化和蛋白酶体降解。在这项研究中,我们使用纯化的蛋白质和直接的体外结合测定、等温滴定量热法和 NMR 光谱学来描述 Vif-EloBC 三元复合物组装的分子机制。我们证明 Vif 在两个位置结合 EloBC,这两种相互作用都诱导 Vif 的 SOCS 盒和 EloBC 的结构发生变化。特别是,除了先前建立的 Vif 的 BC 盒与 EloC 的结合外,我们还报告了 Vif 的保守 Pro-Pro-Leu-Pro 基序与 EloB 的 C 末端结构域之间的新相互作用。通过基于细胞的测定,我们进一步表明,这种相互作用对于形成功能性连接酶复合物是必要的,因此确立了该基序的作用。我们得出结论,HIV-1 Vif 通过一种不需要额外辅助因子的诱导折叠机制与 EloBC 结合,并推测这些特征将 Vif 与其他 EloBC 特异性因子(如细胞 SOCS 蛋白)区分开来,并且可能增强获得 Vif 功能治疗抑制剂的前景。